Optipharm Co Ltd
153710
Company Profile
Business description
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.
Contact
6, 63 Osong, Hwaseong-eup
Heungduk-gu
Chungcheongbuk-do
Cheongju
KORT: +82 432497500
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
77
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,963.50 | 29.20 | 0.33% |
| CAC 40 | 7,800.88 | 33.70 | -0.43% |
| DAX 40 | 23,970.36 | 247.14 | -1.02% |
| Dow JONES (US) | 44,762.98 | 138.94 | -0.31% |
| FTSE 100 | 9,081.44 | 38.87 | -0.43% |
| HKSE | 25,562.13 | 173.78 | 0.68% |
| NASDAQ | 21,139.20 | 30.88 | 0.15% |
| Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
| NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
| S&P 500 | 6,378.28 | 10.36 | -0.16% |
| S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
| SSE Composite Index | 3,597.94 | 4.28 | 0.12% |